Source comparison
Is CJC-1295 No DAC FDA Approved? Research vs Clinical Status
FDA Drug Approval Not approved—classified as research chemical Approved for HIV-associated lipodystrophy (2010) Clinical trials completed vs research-only status CJC-1295 no DAC cannot be legally prescribed or marketed for human therapeutic use Manufacturing O
This comparison does not assign a generated winner or score.
- FDA Drug Approval
- Not approved—classified as research chemical
- Approved for HIV-associated lipodystrophy (2010)
- Clinical trials completed vs research-only status
- CJC-1295 no DAC cannot be legally prescribed or marketed for human therapeutic use
- Manufacturing Oversight
- GMP compliance required for synthesis; third-party purity testing by supplier
- FDA batch-level inspection and potency verification
- Supplier self-regulation vs federal oversight
- Quality variance exists across suppliers—CoA documentation is mandatory
- Legal Purchase Status
- Legal for research institutions and documented lab use
- Prescription-only via licensed pharmacy
- Intended use determines legality
- Purchasing for personal consumption violates federal law regardless of supplier claims
- Clinical Trial Evidence
- Preclinical animal studies only; no Phase III human trials
- Completed Phase III randomized controlled trials in humans
- Experimental vs clinically validated efficacy
- Mechanism understood but therapeutic outcomes in humans remain unproven
- Purity Standards
- ≥98% recommended for research-grade material
- USP-grade purity with defined impurity limits
- Industry standard vs regulatory requirement
- Research peptides lack mandated minimum purity—buyer verification essential
- Half-Life and Dosing
- 30–60 minutes plasma half-life; clears within 2–4 hours
- Similar GHRH mechanism but longer formulation stability
- Both require reconstitution but dosing protocols differ
- Shorter half-life allows flexible experimental dosing windows